Molecular Dissection Of Human Antibody Responses Following Prefusion-Stabilized RSV F Vaccination

2020 ◽  
Author(s):  
Maryam Mukhamedova ◽  
Daniel Wrapp ◽  
Chen-Hsiang Shen ◽  
Morgan S.A. Gilman ◽  
Tracy Ruckwardt ◽  
...  
Keyword(s):  
Antibody Responses ◽  
Human Antibody

scholarly journals Polyclonal epitope mapping reveals temporal dynamics and diversity of human antibody responses to H5N1 vaccination

Cell Reports ◽  
2021 ◽  
Vol 34 (4) ◽  
pp. 108682
Author(s):  
Julianna Han ◽  
Aaron J. Schmitz ◽  
Sara T. Richey ◽  
Ya-Nan Dai ◽  
Hannah L. Turner ◽  
...  
Keyword(s):  
Epitope Mapping ◽  
Temporal Dynamics ◽  
Antibody Responses ◽  
Human Antibody

scholarly journals Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

2020 ◽  
Author(s):  
Davide F. Robbiani ◽  
Christian Gaebler ◽  
Frauke Muecksch ◽  
Julio C. C. Lorenzi ◽  
Zijun Wang ◽  
...  
Keyword(s):  
Virus Entry ◽  
Protein S ◽  
Memory B Cells ◽  
Antibody Responses ◽  
Spike Protein ◽  
Human Antibody ◽  
Receptor Binding Domain ◽  
Single Digit ◽  
Specific Antibodies ◽  
Specific Memory

AbstractDuring the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21–5. Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal neutralizing titers ranging from undetectable in 33% to below 1:1000 in 79%, while only 1% showed titers >1:5000. Antibody cloning revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.

scholarly journals Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

2020 ◽  
Vol 5 (52) ◽  
pp. eabe0367 ◽  
Author(s):  
Anita S. Iyer ◽  
Forrest K. Jones ◽  
Ariana Nodoushani ◽  
Meagan Kelly ◽  
Margaret Becker ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Symptom Onset ◽  
Neutralizing Antibodies ◽  
Serum Antibody ◽  
Cross Reactivity ◽  
Binding Domain ◽  
Antibody Responses ◽  
Human Antibody ◽  
Receptor Binding Domain ◽  
Recent Infection

We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% required hospitalization) up to 122 days after symptom onset and compared them to responses in 1548 individuals whose blood samples were obtained prior to the pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities of 95% for IgG, 90% for IgA, and 81% for IgM for detecting infected individuals between 15 and 28 days after symptom onset. While the median time to seroconversion was nearly 12 days across all three isotypes tested, IgA and IgM antibodies against RBD were short-lived with median times to seroreversion of 71 and 49 days after symptom onset. In contrast, anti-RBD IgG responses decayed slowly through 90 days with only 3 seropositive individuals seroreverting within this time period. IgG antibodies to SARS-CoV-2 RBD were strongly correlated with anti-S neutralizing antibody titers, which demonstrated little to no decrease over 75 days since symptom onset. We observed no cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies with other widely circulating coronaviruses (HKU1, 229 E, OC43, NL63). These data suggest that RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections, and that IgG responses persist over the first few months after infection and are highly correlated with neutralizing antibodies.

Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage

Vaccine ◽  
2010 ◽  
Vol 28 (48) ◽  
pp. 7667-7675 ◽  
Author(s):  
Dlawer A.A. Ala’Aldeen ◽  
Mike Flint ◽  
Neil J. Oldfield ◽  
Sherko A. Omer ◽  
Lisa K. McNeil ◽  
...  
Keyword(s):  
Binding Protein ◽  
Invasive Disease ◽  
Factor H ◽  
Antibody Responses ◽  
Human Antibody

Human antibody responses to Schistosoma mansoni: the influence of epitopes shared between different life-cycle stages on the response to the schistosomulum

1988 ◽  
Vol 18 (1) ◽  
pp. 123-131 ◽  
Author(s):  
David W. Dunne ◽  
Anna M. Grabowska ◽  
Anthony J. C. Fulford ◽  
Anthony E. Butterworth ◽  
Robert F. Sturrock ◽  
...  
Keyword(s):  
Life Cycle ◽  
Schistosoma Mansoni ◽  
Antibody Responses ◽  
Human Antibody ◽  
Life Cycle Stages

scholarly journals Profiling human antibody responses by integrated single-cell analysis

Vaccine ◽  
2014 ◽  
Vol 32 (24) ◽  
pp. 2866-2873 ◽  
Author(s):  
Adebola O. Ogunniyi ◽  
Brittany A. Thomas ◽  
Timothy J. Politano ◽  
Navin Varadarajan ◽  
Elise Landais ◽  
...  
Keyword(s):  
Single Cell ◽  
Single Cell Analysis ◽  
Antibody Responses ◽  
Human Antibody ◽  
Cell Analysis

scholarly journals Age-dependent preference in human antibody responses to Streptococcus pneumoniae polypeptide antigens

2002 ◽  
Vol 127 (2) ◽  
pp. 344-353 ◽  
Author(s):  
S. LIFSHITZ ◽  
R. DAGAN ◽  
M. SHANI-SEKLER ◽  
N. GROSSMAN ◽  
G. FLEMINGER ◽  
...  
Keyword(s):  
Streptococcus Pneumoniae ◽  
Antibody Responses ◽  
Human Antibody ◽  
Age Dependent
Sign in / Sign up

Export Citation Format

Share Document